John Joseph Johnston Sells 3,000 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock

MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston sold 3,000 shares of the firm’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $4.64, for a total transaction of $13,920.00. Following the completion of the transaction, the director now owns 141,950 shares in the company, valued at $658,648. The trade was a 2.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

John Joseph Johnston also recently made the following trade(s):

• On Thursday, December 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The shares were sold at an average price of $4.01, for a total value of $12,030.00.

MaxCyte Stock Performance

NASDAQ MXCT opened at $4.59 on Friday. The stock has a market capitalization of $485.21 million, a PE ratio of -13.50 and a beta of 1.29. The stock has a 50-day simple moving average of $4.23 and a 200 day simple moving average of $4.09. MaxCyte, Inc. has a twelve month low of $3.16 and a twelve month high of $5.29.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. The business had revenue of $8.16 million for the quarter, compared to the consensus estimate of $7.50 million. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. During the same quarter last year, the company posted ($0.11) earnings per share. As a group, equities research analysts forecast that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Marshall Wace LLP bought a new position in MaxCyte during the second quarter valued at about $1,959,000. ArrowMark Colorado Holdings LLC increased its position in shares of MaxCyte by 13.8% during the third quarter. ArrowMark Colorado Holdings LLC now owns 1,394,947 shares of the company’s stock valued at $5,426,000 after purchasing an additional 169,250 shares during the period. Mudita Advisors LLP raised its stake in shares of MaxCyte by 5.6% in the third quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company’s stock valued at $12,267,000 after purchasing an additional 167,101 shares in the last quarter. Gagnon Securities LLC lifted its position in MaxCyte by 234.1% in the fourth quarter. Gagnon Securities LLC now owns 197,326 shares of the company’s stock worth $821,000 after purchasing an additional 138,257 shares during the period. Finally, Barclays PLC boosted its stake in MaxCyte by 329.3% during the third quarter. Barclays PLC now owns 165,765 shares of the company’s stock worth $645,000 after buying an additional 127,156 shares in the last quarter. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.